Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents

癌症化学预防剂的1期和2期临床试验

• 批准号: 8339913
• 负责人: POWELL BROWN
• 金额: $ 168.17万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2014-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8339913
• 关键词: Biological; Biological Markers; Chemoprevention; Chemopreventive Agent; Chronic; Clinical; Clinical Research; Clinical Trials; Contracts; Division of Cancer Prevention; Dose; Drug Kinetics; Institution; Intraepithelial Neoplasia; Malignant Neoplasms; Molecular Target; National Cancer Institute; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Preventive; Research Infrastructure; Safety; Toxic effect; Translational Research; cancer prevention; carcinogenesis; clinically relevant; design; inhibitor/antagonist; insight; novel; triple-negative invasive breast carcinoma

The purpose of this procurement is to conduct multiple early phase (Phase 1 and Phase 2) clinical trials of the National Cancer Institute (NCI), Division of Cancer Prevention (DCP)-sponsored cancer preventive agents and to establish the infrastructures composed of one or more collaborating institutions that will perform these trials. The trials will assess the cancer preventive potential of various agents by evaluating the biologic effects of these agents on their molecular targets and by determining clinically relevant correlates.

此次采购的目的是对国家癌症研究所（NCI）癌症预防部（DCP）赞助的癌症预防剂进行多个早期阶段（1期和2期）临床试验，并建立由一个或多个合作机构组成的基础设施来进行这些试验。这些试验将通过评估这些药物对其分子靶点的生物学效应和确定临床相关因素来评估各种药物的癌症预防潜力。